Lilly(Eli) & Co

NYSE:LLY   3:59:57 PM EDT
-1.89 (-0.77%)
: $245.03 +1.87 (+0.77%)
Strategic Combinations, Earnings Announcements

Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets

Published: 12/13/2021 11:30 GMT
Lilly(Eli) & Co (LLY) - Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform.
Foghorn Therapeutics Inc. - Collaboration Includes Three Additional Discovery Programs.
Foghorn Therapeutics - to Receive $300 Million Upfront and an Equity Investment by Lilly of $80 Million at $20 per Share.
Foghorn Therapeutics - for Brm-selective Program and Additional Undisclosed Target Program, Foghorn Will Lead Discovery and Early Research Activities.
Foghorn Therapeutics Inc. - May Receive Up to a Total of $1.3 Billion in Potential Development and Commercialization Milestones.
Foghorn Therapeutics Inc. - Foghorn and Lilly Will Share 50/50 in U.S. Economics.
Foghorn Therapeutics - Eligible to Receive Royalties on Ex-u.s. Sales Starting in Low Double-digit Range & Escalating Into Twenties Based on Revenue Levels.
Foghorn Therapeutics Inc. - There Will Be No Change to Lilly's 2021 Non-GAAP Earnings per Share Guidance As a Result of Transaction.
Revenue is expected to be $7.52 Billion
Adjusted EPS is expected to be $2.43

Next Quarter Revenue Guidance is expected to be $6.83 Billion
Next Quarter EPS Guidance is expected to be $2.06

More details on our Analysts Page.